Core One Labs Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLABF research report →
Price Chart
About the company
Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin.
- CEO
- Gareth Manderson
- IPO
- 2015
- Employees
- 192
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on CLABF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $471
- P/E
- -0.28
- PEG
- -0.00
- P/S
- 14.89
- P/B
- 0.66
- EV/EBITDA
- -0.41
- Div Yield
- 0.00%
- Gross Margin
- 90.80%
- Op Margin
- -1709.20%
- Net Margin
- -3485.36%
- ROE
- -289.95%
- ROIC
- -112.04%
Latest fiscal year · YoY change
- Revenue
- $458.54K+6.2%
- Gross Profit
- $416.34K+6.0%
- Op Income
- $-7,837,370
- Net Income
- $-15,981,819+56.9%
- EPS
- $-0.49+80.9%
- OCF Growth
- +40.4%
- FCF Growth
- +39.8%
- 52W High
- $0.03
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.54
- RSI (14)
- 52
- Avg Volume
- 53.04K
No earnings-call transcripts are available for CLABF yet.
- Free Float
- 98.4%
- Shares Outstanding
- 47.10M
- Float Shares
- 46.36M
Our CLABF coverage
Recent articles, reports, and earnings notes.
No research on CLABF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLABF report →CSE Bulletin: Delist - Core One Labs Inc. (COOL)
newsfilecorp.com · Sep 19
Core One Enters into Loan Agreement with Right Season Investments
accesswire.com · Jul 8
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
accesswire.com · Dec 8
Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods
accesswire.com · Dec 1
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease
accesswire.com · Aug 4
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
accesswire.com · Aug 1
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease
accesswire.com · Jul 28
Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds
accesswire.com · Jul 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.